Navaneeth Narayanan

Mar 1, 2024 | futuremedicine.com | Sarah M. McLeod |John O'Donnell |Navaneeth Narayanan |John Mills

Acinetobacter baumanniiAcinetobacter baumannii is a difficult-to-treat healthcare-associated pathogen due to its propensity for environmental contamination and multidrug resistance. The Centers for Disease Control and Prevention (CDC)'s 2019 Antibiotic Resistance Threats report listed carbapenem-resistant A. baumannii (CRAB) as an urgent threat to public health. CDC data suggest that CRAB resulted in over 8500 infections, 700 deaths, and $281 million in excess healthcare costs in 2017 [1].